<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The case of a patient with <z:e sem="disease" ids="C0029434" disease_type="Disease or Syndrome" abbrv="">Osteogenesis imperfecta</z:e> is reported who underwent surgery for mitral valve replacement </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0029434" disease_type="Disease or Syndrome" abbrv="">Osteogenesis imperfecta</z:e> is a <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">hereditary disease</z:e> of the connective tissue, associated with <z:hpo ids='HP_0002659'>bone fragility</z:hpo>, bluish colouring of the sclerae, loss of hearing and <z:hpo ids='HP_0000164'>dental anomalies</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0029434" disease_type="Disease or Syndrome" abbrv="">Osteogenesis imperfecta</z:e> is included in a group of hereditary pathologies with <z:e sem="disease" ids="C0013720" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Ehlers-Danlos syndrome</z:e>, <z:e sem="disease" ids="C0086795" disease_type="Disease or Syndrome" abbrv="">Hurler syndrome</z:e>, <z:e sem="disease" ids="C0033847" disease_type="Disease or Syndrome" abbrv="PXE">pseudoxanthoma elasticum</z:e> and <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In the literature there are few cases of patients with <z:e sem="disease" ids="C0029434" disease_type="Disease or Syndrome" abbrv="">osteogenesis imperfecta</z:e> operated for <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> secondary to such disease </plain></SENT>
<SENT sid="4" pm="."><plain>The patient also has a positive family history and a severe <z:hpo ids='HP_0001903'>anaemia</z:hpo>: this was treated with epoetin-alpha and ferrous <z:chebi fb="100" ids="16189">sulphate</z:chebi> during the three weeks before surgery </plain></SENT>
<SENT sid="5" pm="."><plain>The response to epoietin treatment was good while clinical outcome was poor due to rupture of the posterior ventricular wall in the 12th postoperative hour </plain></SENT>
<SENT sid="6" pm="."><plain>The use of epoietin-alpha is discussed </plain></SENT>
</text></document>